Lehner, Louisa http://orcid.org/0009-0000-0524-4985
Thurau, Stephan
Pusl, Konstantin
Tiedt, Steffen
Schöberl, Florian
Forbrig, Robert
Höglinger, Günter
Strupp, Michael
Funding for this research was provided by:
Universitätsklinik München
Article History
Received: 14 October 2023
Revised: 1 November 2023
Accepted: 2 November 2023
First Online: 24 November 2023
Declarations
:
: M. Strupp is Joint Chief Editor of the Journal of Neurology, Editor in Chief of Frontiers of Neuro-otology and Section Editor of F1000. He has received speaker’s honoraria from Abbott, Auris Medical, Biogen, Eisai, Grünenthal, GSK, Henning Pharma, Interacoustics, J&J, MSD, NeuroUpdate, Otometrics, Pierre-Fabre, TEVA, UCB, and Viatris. He receives support for clinical studies from Decibel, U.S.A., Cure within Reach, U.S.A. and Heel, Germany. He distributes “M-glasses” and “Positional vertigo App”. He acts as a consultant for Abbott, AurisMedical, Bulbitec, Heel, IntraBio, Sensorion and Vertify. He is an investor and shareholder in IntraBio. F. Schöberl has received honoraria from Amylyx, Alnylam and Gilead for advisory boards. G. Höglinger has ongoing research collaborations with Roche and UCB; serves as a consultant for Abbvie, Alzprotect, Amylyx, Aprineua, Asceneuron, Bayer, Bial, Biogen, Biohaven, Epidarex, Ferrer, Kyowa Kirin, Lundbeck, Novartis, Retrotope, Roche, Sanofi, Servier, Takeda, Teva, UCB; received honoraria for scientific presentations from Abbvie, Bayer, Bial, Biogen, Bristol Myers Squibb, Kyowa Kirin, Pfizer, Roche, Teva, UCB, Zambon; holds a patent on the treatment of Synucleinopathies (US 10,918,628 B2, EP 17 787 904.6-1109/3 525 788); received publication royalties from Academic Press, Kohlhammer, and Thieme. The other authors declare no conflict of interest.
: This article does not contain any studies with human participants or animals performed by any of the authors.
: The participant has consented to the submission of the case report to the journal.